focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.50
Bid: 43.00
Ask: 44.00
Change: -0.75 (-1.69%)
Spread: 1.00 (2.326%)
Open: 44.25
High: 44.25
Low: 43.25
Prev. Close: 44.25
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks falter amid weaker outlook for China

Mon, 19th Jun 2023 09:09

(Alliance News) - Stock prices in London opened lower on Monday, ahead of more interest rate decisions, and amid fears for China's slowing economic recovery.

The FTSE 100 index opened down 21.77 points, 0.3% at 7,620.95. The FTSE 250 was down 72.37 points, 0.4%, at 18,958.52, and the AIM All-Share was down 1.33 points, 0.2%, at 791.26.

The Cboe UK 100 was down 0.3% at 760.24, the Cboe UK 250 was down 0.3% at 16,563.48, and the Cboe Small Companies was down 0.1% at 13,935.74.

The pound held on to recent gains ahead of the Bank of England's interest rate decision on Thursday, with the bank expected to enact a 25 basis point hike. There will be UK inflation data on Wednesday.

Sterling was quoted at USD1.2821 early Monday, higher than USD1.2819 at the London equities close on Friday.

"The anticipated rise to 4.75% is not seen to be the end of the story, however," said interactive investor's Richard Hunter.

"Some [are] predicting a terminal rate of nearer 6%, which would put additional strain on an economy wrought with tepid growth and a tight labour market."

The euro traded at USD1.0931 early Monday, higher than USD1.0926 late Friday. Against the yen, the dollar was quoted at JPY141.68, up a touch versus JPY141.59.

There will also be interest rate decisions from the People's Bank of China on Tuesday, and the Swiss National Bank on Thursday.

Financial markets in New York are closed on Monday for the Juneteenth holiday, which is likely to suppress trading volumes across the globe.

In the US on Friday, Wall Street ended in the red, with the Dow Jones Industrial Average down 0.3%, the S&P 500 down 0.4% and the Nasdaq Composite down 0.7%

Asian equities were mostly weaker, amid lower growth forecasts for China. Goldman Sachs cut its forecasts for Chinese economic growth to 6% from 5.4% previously.

The Nikkei 225 index in Tokyo closed down 1.0%. In China, the Shanghai Composite closed down 0.5%, while the Hang Seng index in Hong Kong was down 1.1%. The S&P/ASX 200 in Sydney closed up 0.6%.

"The China GDP downgrades have darkened the outlook in a week many had high hopes," said SPI Asset Management's Stephen Innes.

London's mining stocks fell on the weaker outlook for demand from China, with Antogafasta and Anglo American both down 1.9%.

"For now, the darker economic outlook has pushed backed optimism around the PBoC stimulus and hopes for a thawing in frosty China-US relations," Innes continued.

US Secretary of State Antony Blinken met with his Chinese counterpart Qin Gang at the start of his two-day trip to Beijing, a visit aimed at rebuilding the cratering relationship between the world's two largest economies.

A series of meetings with high-ranking government representatives are planned before Blinken - the most senior US official to visit China in years - leaves on Monday.

According to a US official speaking anonymously to AFP, Blinken will meet with President Xi Jinping later in the day - a symbolic sign of support for efforts to improve ties.

The heightening of tension between the US and China has taken its toll on business confidence in recent months. The Financial Times reports that AstraZeneca is mulling a spin-off of its Chinese business and listing it in Hong Kong, to better insulate the unit from the geopolitical friction between China and the US and its allies.

Citing sources familiar with the talks, the FT said the separation might not take place, or a Shanghai listing is also possible.

"A spin-off could potentially allow AstraZeneca to circumvent any potential regulatory clampdown on global pharma companies from Beijing and could also expedite its drug approvals pipeline in China where the FTSE 100 pharma giant generated 13% of its total sales last year," ii's Victoria Scholar considered.

Astra fell 0.8% in early trade on Monday in London.

Meanwhile, in Frankfurt, pharmaceutical and laboratory equipment supplier Sartorius dropped 15%.

Late Friday, it had warned that it expects revenue for 2023 to be below expectations, mainly due to the longer-lasting reduction of biopharma customer inventories due to Covid-19, as well as low investment activity.

In European equities on Monday, the CAC 40 in Paris was down 0.5%, while the DAX 40 in Frankfurt was down 0.4%.

UK house prices suffered a marginal fall this month, the first June decline since 2017, according to a Rightmove tracker.

Average new seller asking prices fell by just GBP82 in June to GBP372,812 from GBP372,894. Prices had risen 1.8% in May from April. Though fractional, June's outturn was the first monthly drop in asking prices this year, and was the first June fall in house prices since 2017.

Housebuilder Taylor Wimpey shed 1.0%, but fellow housebuilder Persimmon rose 0.6%.

Elsewhere in the FTSE 100, Entain was among the top performers, up 1.4%. Redburn raised the gambling company's stock to 'buy'.

Coca-Cola HBC fell 2.7%, as it announced it will acquire Brown-Forman Finland, which owns the Finlandia vodka brand, from Brown-Forman's Dutch subsidiary. It will pay USD220 million, and expects the acquisition to complete in the second half. It is subject to regulatory approvals.

"Having been associated with the distribution of Finlandia for 17 years in several markets, we are excited by this unique and regionally relevant opportunity that will support the acceleration of our on-premise business across more of our markets," said Chief Executive Zoran Bogdanovic.

Among midcaps, Kainos Group fell 2.3%,

The IT services provider announced its CEO of 22 years, Brendan Mooney, will step down by the end of September, with Digital Services Director Russell Sloan replacing him.

Mooney will remain "actively engaged" with the business until next June, to ensure an orderly transition, the company said.

On AIM, Avacta Group rose 8.3%.

The life sciences firm denied media reports of plans for an imminent fundraising. "The company regularly considers potential funding opportunities, both non-dilutive and dilutive, to ensure its business operations remain well financed and the best interests of its stakeholders are maintained," it explained.

Avacta said whilst it "[maintains] a dialogue" with shareholders and current investors, "no fundraising is imminent".

It had cash of GBP27 million on the balance sheet at the end of May, and expects "strong news flow" in the coming months across the company.

Brent oil was quoted at USD75.83 a barrel early in London on Monday, little changed from USD75.62 late Friday.

Gold was quoted at USD1,954.31 an ounce, down against USD1,960.83.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 Jun 2021 20:24

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

Read more
1 Jun 2021 11:16

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.

Read more
28 May 2021 11:29

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on response from UK regulator over Covid test

Read more
28 May 2021 07:29

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

Read more
10 May 2021 11:13

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

Read more
22 Apr 2021 12:17

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Read more
20 Apr 2021 15:18

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

Read more
20 Apr 2021 12:17

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

Read more
20 Apr 2021 11:35

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

Read more
15 Apr 2021 14:56

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
6 Apr 2021 13:53

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

Read more
6 Apr 2021 11:03

Avacta signs global distribution deal with Abcam

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.

Read more
25 Mar 2021 15:57

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

Read more
9 Mar 2021 20:19

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

Read more
9 Mar 2021 11:08

Avacta enters licence deal with Werfen subsidiary Biokit

(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.